1
|
Ye RH, Zhang YQ, Cao DD, Shi Y, Xiao GF, Li PY, Xu YW, Wei H, Sun JT, Yang YC, Tang RH, Wang JB, He N, Ding YY, Duan S. [Incidence of diabetes and influencing factors in HIV-infected individuals after antiretroviral therapy in Dehong Dai and Jingpo Autonomous Prefecture]. Zhonghua Liu Xing Bing Xue Za Zhi 2024; 45:358-364. [PMID: 38514312 DOI: 10.3760/cma.j.cn112338-20230817-00075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 03/23/2024]
Abstract
Objective: To understand the incidence of diabetes and influencing factors, the trend of FPG change and risk for mortality in HIV-infected individuals after antiretroviral therapy (ART) in Dehong Dai and Jingpo Autonomous Prefecture (Dehong). Methods: The HIV/AIDS treatment database was collected from China Information System for Disease Control and Prevention. This retrospective cohort study was conducted in HIV-infected individuals with access to ART in Dehong during 2004-2020.The Cox proportional hazard regression model was used to analyze the incidence density of diabetes, the influencing factors and risk for mortality in HIV-infected individuals with access to ART, mixed linear effects model was used to analyze the trend of FPG change and predict FPG in those with different glucose metabolic status at baseline survey. Statistical analysis was performed using software SAS 9.4. Results: A total of 8 763 HIV-infected individuals were included, in whom 8 432 (96.2%) had no diabetes, 331 had diabetes. The incidence density of diabetes was 2.31/1 000 person years. Multivariate Cox proportional hazard regression analysis revealed that 30- 59 years old, BMI ≥24.0 kg/m2, Efavirenz (EFV) based initial treatment regimen and impaired fasting glucose (IFG) at baseline survey were significantly and positively associated with incidence of diabetes. Mixed effect model revealed that FPG was positively correlated with the duration of ART, age and baseline FPG. Suffering from diabetes was a risk factor for mortality in HIV-infected individuals both at baseline survey and during follow-up. Conclusions: The risk for diabetes increased in HIV-infected individuals who were 30-59 years old, baseline BMI ≥24.0 kg/m2, received EFV based initial treatment, and IFG in HIV-infected individuals after antiretroviral therapy in Dehong, 2004-2020. It is important to pay close attention to their blood glucose, and patients with high blood glucose should receive treatment as early as possible.
Collapse
Affiliation(s)
- R H Ye
- Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
| | - Y Q Zhang
- Department of Epidemiology, Key Laboratory of Public Health Safety of Ministry of Education, School of Public Health, Fudan University, Shanghai 200032, China
| | - D D Cao
- Dehong Dai and Jingpo Autonomous Prefecture People's Hospital, Mangshi 678400, China
| | - Y Shi
- Mangshi People's Hospital of Dehong Dai and Jingpo Autonomous Prefecture, Mangshi 678400, China
| | - G F Xiao
- Dehong Dai and Jingpo Autonomous Prefecture Hospital of Traditional Chinese Medicine, Mangshi 678400, China
| | - P Y Li
- Ruili City People's Hospital of Dehong Dai and Jingpo Autonomous Prefecture, Ruili 678600, China
| | - Y W Xu
- Longchuan County People's Hospital of Dehong Dai and Jingpo Autonomous Prefecture, Longchuan 678700, China
| | - H Wei
- Yingjiang County People's Hospital of Dehong Dai and Jingpo Autonomous Prefecture, Yingjiang 679300, China
| | - J T Sun
- Lianghe County People's Hospital of Dehong Dai and Jingpo Autonomous Prefecture, Lianghe 679200, China
| | - Y C Yang
- Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
| | - R H Tang
- Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
| | - J B Wang
- Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
| | - N He
- Department of Epidemiology, Key Laboratory of Public Health Safety of Ministry of Education, School of Public Health, Fudan University, Shanghai 200032, China
| | - Y Y Ding
- Department of Epidemiology, Key Laboratory of Public Health Safety of Ministry of Education, School of Public Health, Fudan University, Shanghai 200032, China
| | - S Duan
- Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
| |
Collapse
|
2
|
Yao ST, He CY, Cao DD, Zhang YD, Shi Y, Xiao GF, Li PY, Xu YW, Wei H, Sun JT, Ye RH, Yang YC, Wang JB, He N, Ding YY, Duan S. [A retrospective cohort study of incidence of anemia and risk factors in HIV/AIDS patients with access to antiretroviral therapy in Dehong Jingpo and Dai Autonomous Prefecture in Yunnan province, 2004-2018]. Zhonghua Liu Xing Bing Xue Za Zhi 2021; 42:1218-1224. [PMID: 34814534 DOI: 10.3760/cma.j.cn112338-20200602-00799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Objective: To investigate the incidence of anemia and risk factors in HIV/AIDS patients with access to antiretroviral therapy (ART) during 2004-2018 in Dehong Jingpo and Dai Autonomous Prefecture (Dehong). Methods: A retrospective cohort study was conducted in HIV/AIDS patients receiving ART in Dehong during 2004-2018 based on the data extracted from the National HIV/AIDS antiretroviral therapy database. Cox proportional risk model was used to analyze the factors associated with the incidences of anemia and moderate or severe anemia in the HIV/AIDS patients. And the piecewise linear mixed-effects model was used to depict the trajectory of hemoglobin changes over time after initiating ART according to baseline level. Results: A total of 8 044 HIV/AIDS patients were included, in whom 6 337 (78.8%) were without anemia at baseline survey and had a median follow up time of 4.43 (P25, P75: 1.50, 6.71) years. The median follow up time for 1 291 new anemia cases and 293 new moderate or severe anemia cases was 0.16 (P25, P75: 0.07, 1.99) years and 0.48 (P25, P75:0.09, 2.97) years, respectively. The incidence rate of anemia and moderate or severe anemia was 4.40 per 100 person-years and 0.41 per 100 person-years respectively. In multivariable Cox regression analysis, older age, being female, being in Dai and Jingpo ethnic group, baseline BMI <18.5 kg/m2, baseline CD4+T lymphocyte cell counts (CD4) <200 cells/μl, and zidovudine (AZT) -based initial treatment regimen were factors significantly and positively associated with incidence of anemia after treatment. Factors as being female, being in Dai ethnic group, baseline BMI <18.5 kg/m2, mild baseline anemia, and AZT-based initial treatment regimen were significantly and positively associated with incidence of moderate or severe anemia after treatment. Conclusion: The risk for anemia was higher in HIV/AIDS patients with specific characteristics, such as age ≥60 years , being female, being in Dai and Jingpo ethnic groups, lower BMI, CD4 <200 cells/μl, and treatment of AZT, after initiation of ART in Dehong during 2004-2018. Additional efforts are needed to strengthen the screening, prevention and treatment of anemia in this population.
Collapse
Affiliation(s)
- S T Yao
- Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
| | - C Y He
- Department of Epidemiology, Key Laboratory of Public Health Safety of Ministry of Education, School of Public Health, Fudan University, Shanghai 200032, China
| | - D D Cao
- Dehong Dai and Jingpo Autonomous Prefecture People's Hospital, Mangshi 678400, China
| | - Y D Zhang
- Dehong Dai and Jingpo Autonomous Prefecture People's Hospital, Mangshi 678400, China
| | - Y Shi
- Mangshi City People's Hospital of Dehong Dai and Jingpo Autonomous Prefecture, Mangshi 678400, China
| | - G F Xiao
- Traditional Chinese Medicine Hospital of Dehong Dai and Jingpo Autonomous Prefecture, Mangshi 678400, China
| | - P Y Li
- Ruili City People's Hospital of Dehong Dai and Jingpo Autonomous Prefecture, Ruili 678600, China
| | - Y W Xu
- Longchuan County People's Hospital of Dehong Dai and Jingpo Autonomous Prefecture, Longchuan 678700, China
| | - H Wei
- Yingjiang County People's Hospital of Dehong Dai and Jingpo Autonomous Prefecture, Yingjiang 679300, China
| | - J T Sun
- Lianghe County People's Hospital of Dehong Dai and Jingpo Autonomous Prefecture, Lianghe 679200, China
| | - R H Ye
- Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
| | - Y C Yang
- Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
| | - J B Wang
- Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
| | - N He
- Department of Epidemiology, Key Laboratory of Public Health Safety of Ministry of Education, School of Public Health, Fudan University, Shanghai 200032, China
| | - Y Y Ding
- Department of Epidemiology, Key Laboratory of Public Health Safety of Ministry of Education, School of Public Health, Fudan University, Shanghai 200032, China
| | - S Duan
- Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
| |
Collapse
|
3
|
Yao ST, He CY, Cao DD, Zhang YD, Shi Y, Li PY, Feng YL, Wei H, Xiao GF, Sun JT, Ye RH, Yang YC, Wang JB, He N, Ding YY, Duan S. [Incidence and influencing factors of AIDS-related and non-AIDS-related deaths after receiving antiretroviral therapy among HIV-positive individuals in Dehong Dai and Jingpo Autonomous Prefecture, 2010-2019]. Zhonghua Liu Xing Bing Xue Za Zhi 2021; 42:632-637. [PMID: 34814442 DOI: 10.3760/cma.j.cn112338-20200903-01121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Objective: To explore the changing trends and influencing factors of AIDS-related and non-AIDS-related deaths after receiving antiretroviral therapy (ART) among HIV-positive individuals in Dehong Dai Jingpo autonomous prefecture (Dehong) from 2010 to 2019. Methods: Based on the Chinese National treatment database, HIV patients who initiated ART from 2010 to 2019 were included in the analysis. The cumulative incidence function was used to estimate the cumulative incidence of AIDS-related death and non-AIDS-related death, respectively. The Fine-Grey model was used to compare the differences between AIDS-related and non-AIDS-related deaths and analyze its influencing factors. Results: A total of 7 068 HIV-positive individuals were included, of which 388 were AIDS-related deaths and 570 were non-AIDS-related deaths. The cumulative mortality rate at years 1, 2, 3, 4, 5, 7 and 9 after receiving ART were 2.27%, 3.46%, 4.47%, 5.03%, 5.84%, 6.61%, 7.40% for AIDS-related deaths, and 1.63%, 3.11%, 4.68%, 6.02%, 7.42%, 10.49%, 12.75% for non-AIDS-related deaths, respectively. In the Fine-Grey model, older age at ART initiation, male, unmarried, injection drug use as the transmission route, lower baseline BMI, lower baseline CD4+ T cell counts, baseline FIB-4 score >3.25, and baseline anemia were risk factors for AIDS-related death. In contrast, age at ART initiation ≥45 years, male, Dai, and Jingpo minority ethnicities, unmarried, injection drug use as the transmission route, lower baseline BMI, baseline FIB-4 score >3.25, baseline eGFR <60 ml·min-1·1.73 m-2, and baseline anemia were risk factors for non-AIDS-related deaths. Conclusions: The cumulative mortality rate was low among HIV-positive individuals after receiving ART in Dehong during 2010-2019. The mortality of non-AIDS-related deaths was higher than that of AIDS-related deaths. There were also differences in the factors influencing AIDS-related and non-AIDS-related deaths and interventions should be intensified to target the influencing factors for non-AIDS-related deaths.
Collapse
Affiliation(s)
- S T Yao
- Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
| | - C Y He
- Department of Epidemiology, School of Public Health, Key Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai 200032, China
| | - D D Cao
- People's Hospital of Dehong Dai and Jingpo Autonomous Prefecture, Mangshi 678400, China
| | - Y D Zhang
- People's Hospital of Dehong Dai and Jingpo Autonomous Prefecture, Mangshi 678400, China
| | - Y Shi
- Mangshi City People's Hospital, Mangshi 678400, China
| | - P Y Li
- Ruili City People's Hospital, Ruili 678600, China
| | - Y L Feng
- Longchuan County People's Hospital, Longchuan 678700, China
| | - H Wei
- Yingjiang County People's Hospital, Yingjiang 679300, China
| | - G F Xiao
- Dehong Dai and Jingpo Autonomous Prefecture Hospital of Traditional Chinese Medicine, Mangshi 678400, China
| | - J T Sun
- Lianghe County People's Hospital, Lianghe 679200, China
| | - R H Ye
- Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
| | - Y C Yang
- Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
| | - J B Wang
- Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
| | - N He
- Department of Epidemiology, School of Public Health, Key Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai 200032, China
| | - Y Y Ding
- Department of Epidemiology, School of Public Health, Key Laboratory of Public Health Safety, Ministry of Education, Fudan University, Shanghai 200032, China
| | - S Duan
- Dehong Dai and Jingpo Autonomous Prefecture Center for Disease Control and Prevention, Mangshi 678400, China
| |
Collapse
|
4
|
Xiao GF, Yan X, Chen Z, Zhang RJ, Liu TZ, Hu WL. Identification of a Novel Immune-Related Prognostic Biomarker and Small-Molecule Drugs in Clear Cell Renal Cell Carcinoma (ccRCC) by a Merged Microarray-Acquired Dataset and TCGA Database. Front Genet 2020; 11:810. [PMID: 33014010 PMCID: PMC7461880 DOI: 10.3389/fgene.2020.00810] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Accepted: 07/06/2020] [Indexed: 12/13/2022] Open
Abstract
Clear cell renal cell carcinoma (ccRCC) is one of the most common histological subtypes of renal cancer, with a poor prognosis. Our study aimed to identify a biomarker that is significantly associated with ccRCC prognosis and novel immunotherapeutic targets, as well as some novel molecular drugs for ccRCC. Based on the overlap of The Cancer Genome Atlas (TCGA)-Kidney Renal Clear Cell Carcinoma (KIRC) data and the ImmPort database, we obtained 1,292 immune-related genes (IRGs) and constructed a weighed co-expression network based on the IRGs. A total of 39 hub genes were screened out in three modules. CTLA4, which had the highest connectivity degree among the screened genes in a protein–protein interaction network (degree = 24), was selected. Internal validation based on the GEPIA database revealed that patients with a higher expression of CTLA4 had a significantly shorter overall survival time and disease-free survival time. Expression of CTLA4 was also closely correlated with local recurrence, pathologic stage, and immune infiltration level. External validation based on the Oncomine database and merged microarray-acquired dataset validated the mRNA expression level of hub genes. Gene-set enrichment analysis revealed that six KEGG signaling pathways, which were significantly associated with CTLA4, were enriched on immune-related pathways. Further analysis according to the TIMER database demonstrated that CTLA4 expression was positively related to dendritic cells (cor = 0.446, P = 1.32E-23) and negatively associated with tumor purity (cor = −0.267, P = 5.51E-09). Finally, we screened out 293 differentially expressed genes by integrating six datasets from the GEO database. The Connectivity Map (CMap) analysis revealed the strong potential of three small molecule drugs (monensin, quercetin, and fenbufen) for ccRCC treatment. In conclusion, CTLA4 was identified and validated in prognosis of ccRCC. CTLA4 may be a new prognostic biomarker and immunotherapeutic target for ccRCC. Monensin, quercetin, and fenbufen may be novel choices for ccRCC treatment.
Collapse
Affiliation(s)
- Guan-Fa Xiao
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.,Department of Pediatric surgery, Ganzhou Maternal and Child Health Hospital, Ganzhou, China
| | - Xin Yan
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Zhao Chen
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Ren-Jie Zhang
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Tong-Zu Liu
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Wan-Li Hu
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China
| |
Collapse
|
5
|
Chen Z, Yan X, Du GW, Tuoheti K, Bai XJ, Wu HH, Zhang RJ, Xiao GF, Liu TZ. Complement C7 (C7), a Potential Tumor Suppressor, Is an Immune-Related Prognostic Biomarker in Prostate Cancer (PC). Front Oncol 2020; 10:1532. [PMID: 32984006 PMCID: PMC7477933 DOI: 10.3389/fonc.2020.01532] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2019] [Accepted: 07/16/2020] [Indexed: 12/24/2022] Open
Abstract
Objectives: Prostate cancer (PC) is the second most frequent tumor in men, which has a high recurrence rate and poor prognosis. Therefore, this study aimed to identify novel prognostic biomarkers and therapeutic targets for immunotherapy and small molecule drugs for PC treatment. Materials and Methods: The Estimation of Stromal and Immune cells in Malignant Tumor tissues using Expression data (ESTIMATE) algorithm was applied to calculate immune scores and stromal scores of TCGA-PRAD data. Differentially expressed genes (DEGs) were identified using R package “limma.” GO, KEGG, and DO analyses were performed to analyze DEGs. Overall survival and disease-free survival analyses were conducted for hub gene identification. To validate the hub gene at the mRNA and protein expression levels, genetic alterations were measured, and CCLE and Cox regression analyses were performed. Connectivity map (CMap) analysis and GSEA were performed for drug exploration and function analysis, respectively. Results: Immune scores ranged from −1795.98 to 2339.39, and stomal scores ranged from −1877.60 to 1659.96. In total, 45 tumor microenvironment (TME)-related DEGs were identified, of which Complement C7 (C7) was selected and validated as a hub gene. CMap analysis identified six small molecule drugs as potential agents for PC treatment. Further analysis demonstrated that C7 expression was significantly correlated with clinical T, pathological N, and immune infiltration level. Conclusions: In conclusion, of the 45 TME-related DEGs, C7 was shown to correlate with PC prognosis in patients, indicating it as a novel prognostic biomarker and immunotherapy target in PC. Additionally, six small molecule drugs showed strong therapeutic potential for PC treatment.
Collapse
Affiliation(s)
- Zhao Chen
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Xin Yan
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Guo-Wei Du
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Kurerban Tuoheti
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Xiao-Jie Bai
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Hua-Hui Wu
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Ren-Jie Zhang
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Guan-Fa Xiao
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - Tong-Zu Liu
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China
| |
Collapse
|
6
|
Li C, Hu WL, Lu MX, Xiao GF. Resveratrol induces apoptosis of benign prostatic hyperplasia epithelial cell line (BPH-1) through p38 MAPK-FOXO3a pathway. BMC Complement Altern Med 2019; 19:233. [PMID: 31464618 PMCID: PMC6714439 DOI: 10.1186/s12906-019-2648-8] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/29/2018] [Accepted: 08/21/2019] [Indexed: 12/11/2022]
Abstract
Background Resveratrol is reported to inhibit the growth of prostate, which is characteristic of benign prostatic hyperplasia (BPH) condition. However, the mechanism remains unclear. This study aimed to identify the effects and probable mechanism of resveratrol on BPH. Methods We used the BPH epithelial cell line BPH-1 to investigate the effect of resveratrol. Cells were treated with various concentrations of resveratrol, and its effects on cells viability, apoptosis, ROS accumulation, and cell cycle were assessed. Western blot was used to examine activation of p38 MAPK and protein levels of FOXO3a, Bcl2, Bcl-XL, and caspase3. Cells were also co-treated with the p38 MAPK inhibitor SB203580 or ROS scavenger N-Acetyl-L-cysteine (NAC) to further investigate the mechanism. Results Resveratrol treatment inhibited the growth of BPH-1 and increased apoptosis of cells. In addition, levels of phosphorylated p38 MAPK level was elevated and FOXO3a repression was observed. Concomitantly, ROS was accumulated. All of these resveratrol-mediated effects were suppressed by additional treatment with SB203580 or NAC. Resveratrol was also found to induce cell cycle arrest at S phase. Conclusions Resveratrol can activate p38 MAPK and repress FOXO3a, thereby causing repression of SOD2, catalase, and increase of ROS accumulation, leading to apoptosis in BPH-1 cells.
Collapse
|
7
|
Xie LD, Zhuang W, Lian GL, Huang BB, Du AP, Xiao GF, Gong J, Xu CS, Wang HJ. P1861Proliferation of pulmonary artery smooth muscle cells could be regulated by carnitine palmitoyltransferase 1. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- L D Xie
- The First affiliated Hospital of Fujian Medical University, Fuzhou, China People's Republic of
| | - W Zhuang
- The First affiliated Hospital of Fujian Medical University, Fuzhou, China People's Republic of
| | - G L Lian
- Fujian Hypertension Research Institute, Fuzhou, China People's Republic of
| | - B B Huang
- The First affiliated Hospital of Fujian Medical University, Fuzhou, China People's Republic of
| | - A P Du
- Fujian Hypertension Research Institute, Fuzhou, China People's Republic of
| | - G F Xiao
- Fujian Hypertension Research Institute, Fuzhou, China People's Republic of
| | - J Gong
- Fujian Hypertension Research Institute, Fuzhou, China People's Republic of
| | - C S Xu
- Fujian Hypertension Research Institute, Fuzhou, China People's Republic of
| | - H J Wang
- Fujian Hypertension Research Institute, Fuzhou, China People's Republic of
| |
Collapse
|
8
|
Zhuang W, Lian GL, Huang BB, Du AP, Xiao GF, Gong J, Wang HJ, Xu CS, Xie LD. P1856Pulmonary arterial hypertension induced by a novel twice-intraperitoneal injection of monocrotaline. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- W Zhuang
- The First affiliated Hospital of Fujian Medical University, Fuzhou, China People's Republic of
| | - G L Lian
- Fujian Hypertension Research Institute, Fuzhou, China People's Republic of
| | - B B Huang
- The First affiliated Hospital of Fujian Medical University, Fuzhou, China People's Republic of
| | - A P Du
- Fujian Hypertension Research Institute, Fuzhou, China People's Republic of
| | - G F Xiao
- Fujian Hypertension Research Institute, Fuzhou, China People's Republic of
| | - J Gong
- Fujian Hypertension Research Institute, Fuzhou, China People's Republic of
| | - H J Wang
- Fujian Hypertension Research Institute, Fuzhou, China People's Republic of
| | - C S Xu
- Fujian Hypertension Research Institute, Fuzhou, China People's Republic of
| | - L D Xie
- The First affiliated Hospital of Fujian Medical University, Fuzhou, China People's Republic of
| |
Collapse
|
9
|
Xu XM, Zhou YQ, Luo GX, Liao C, Zhou M, Chen PY, Lu JP, Jia SQ, Xiao GF, Shen X, Li J, Chen HP, Xia YY, Wen YX, Mo QH, Li WD, Li YY, Zhuo LW, Wang ZQ, Chen YJ, Qin CH, Zhong M. The prevalence and spectrum of alpha and beta thalassaemia in Guangdong Province: implications for the future health burden and population screening. J Clin Pathol 2004; 57:517-22. [PMID: 15113860 PMCID: PMC1770296 DOI: 10.1136/jcp.2003.014456] [Citation(s) in RCA: 270] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/28/2003] [Indexed: 11/04/2022]
Abstract
AIM Thalassaemia is a good candidate disease for control by preventive genetic programmes in developing countries. Accurate population frequency data are needed for planning the control of thalassaemia in the high risk Guangdong Province of southern China. METHODS In total, 13397 consecutive samples from five geographical areas of Guangdong Province were analysed for both haematological and molecular parameters. RESULTS There was a high prevalence of carriers of alpha thalassaemia (8.53%), beta thalassaemia (2.54%), and both alpha and beta thalassaemia (0.26%). Overall, 11.07% of the population in this area were heterozygous carriers of alpha and beta thalassaemia. The mutation spectrum of alpha and beta thalassaemia and its constitution were fully described in this area. This study reports the true prevalence of silent alpha thalassaemia in the southern China population for the first time. In addition, two novel mutations that give rise to alpha thalassaemia, one deletion resulting in beta thalassaemia, and a rare deletion (--(THAI) allele) previously unreported in mainland China were detected. The frequency of the most common mutation, the Southeast Asian type of deletion (--(SEA), accounting for 48.54% of all alpha thalassaemias) was similar to the total of two alpha(+) thalassaemia deletions (-alpha(3.7) and -alpha(4.2), accounting for 47.49% of alpha thalassaemia). CONCLUSION Both alpha and beta thalassaemia are widely distributed in Guangdong Province of China. The knowledge gained in this study will enable the projected number of pregnancies at risk to be estimated and a screening strategy for control of thalassaemia to be designed in this area.
Collapse
Affiliation(s)
- X M Xu
- Department of Medical Genetics, First Military Medical University, Guangzhou 510515, Guangdong, PR China.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Xiao GF. [Traditional Chinese medicine and Western medicine in the treatment of sputum-positive tuberculosis; short-term follow-up studies]. Zhong Xi Yi Jie He Za Zhi 1987; 7:158-60, 133. [PMID: 3607965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
11
|
Xu BZ, Sha R, Xiao GF, Zhou XT. A fragile X syndrome family. Chin Med J (Engl) 1984; 97:861-4. [PMID: 6443280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
|